Interius BioTherapeutics Doses First Patient with in vivo Chimeric Antigen Receptor (CAR) Gene Therapy for B-cell Malignancies - Yahoo Finance

INT2104 is a novel in vivo chimeric antigen receptor (CAR) gene therapy designed to generate CAR-T and CAR-NK cells in the patient’s body to target CD20-expressing malignant B cells Interim ... Read More

University of Pennsylvania gene therapy spinout Interius BioTherapeutics doses patient, achieves CAR therapy first

University of Pennsylvania gene therapy spinout Interius BioTherapeutics doses patient, achieves CAR therapy first. ... Area cell and gene therapy firms account for 10% of global industry. Read More

Interius BioTherapeutics Launches Innovative Gene Therapy Trial for B-Cell Malignancies - MSN

PHILADELPHIA, PA — Interius BioTherapeutics has taken a significant step forward with the dosing of its first participant in the Phase 1 clinical trial of INT2104, a pioneering gene therapy ... Read More

Interius BioTherapeutics receives approval for B-cell malignancy therapy trial - Yahoo Finance

INT2104 is an investigational in vivo chimeric antigen receptor (CAR) gene therapy candidate. The drug targets the CD7-positive T and NK cells and provides a CAR transgene to create effector CAR-T ... Read More

Interius BioTherapeutics Receives HREC Approval and CTN Clearance from the TGA to Commence a Phase 1 Clinical Trial for Its First-in-Class In Vivo CAR Therapeutic for B Cell ...

Will initiate a first-in-human Phase 1 clinical trial for INT2104, its first-in-class in vivo targeted gene therapy, creating CAR cells for the treatment of B cell malignancies in 4Q24 ... Read More

Interius BioTherapeutics Doses First Patient with in vivo Chimeric Antigen Receptor (CAR) Gene Therapy for B-cell Malignancies - KTLA

INT2104 is a novel in vivo chimeric antigen receptor (CAR) gene therapy designed to generate CAR-T and CAR-NK cells in the patient’s body to target CD20-expressing malignant B cells Interim ... Read More

Interius BioTherapeutics Doses First Patient with in vivo Chimeric Antigen Receptor (CAR) Gene Therapy for B-cell Malignancies - Yahoo Finance

INT2104 is a novel in vivo chimeric antigen receptor (CAR) gene therapy designed to generate CAR-T and CAR-NK cells in the patient’s body to target CD20-expressing malignant B cells Interim safety and ... Read More

Interius BioTherapeutics Doses First Patient with in vivo Chimeric Antigen Receptor (CAR) Gene Therapy for B-cell Malignancies

INT2104 is a novel in vivo chimeric antigen receptor (CAR) gene therapy designed to generate CAR-T and CAR-NK cells in the patient’s body to target CD20-expressing malignant B cells Interim ... Read More

Interius BioTherapeutics Doses First Patient with in vivo Chimeric Antigen Receptor (CAR) Gene Therapy for B-cell Malignancies - The Manila Times

INT2104 is a novel in vivo chimeric antigen receptor (CAR) gene therapy designed to generate CAR-T and CAR-NK cells in the patient's body to target CD20-expressing malignant B cells Interim safety and ... Read More